eRegister's captcha

Patent Register Details

Print page icon Print this page

PATENT REGISTER
A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2015/040 2016/042
Status Revoked by EPO Patent No. 1641822
Application No. 04754234.5 Date of Filing 02/06/2004
Date Grant Published 15/05/2013 Application Published 10/01/2005
Title of Invention IL-17 A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
Priority
Priority Country Filing Date Application No.
 United States of America  08/07/2003  485599 P
 United States of America  11/07/2003  486457 P
Inventors ARNOTT, David
GURNEY, Austin
HASS, Philip
LEE, James
WU, Yan
Current Proprietor Genentech, Inc.
1 DNA Way
South San Francisco CA 94080-4990
UNITED STATES OF AMERICA
Address for service F.F. GORMAN & CO.
15 Clanwilliam Square
Dublin 2
IRELAND
Renewal Fees
Year Date Renewed
 16  24/05/2019
 15  28/05/2018
 14  26/05/2017
 13  26/05/2016
 12  09/06/2015
 11  29/05/2014
 10  26/07/2013
Publication Language English
Translation Received Date
23/05/2013 Divisional Application number: 10010285.4 Publication number: 2277908 Date of receipt: 23/09/2010
21/06/2013 Address for Service recorded as F.F. GORMAN & CO., 15 Clanwilliam Square, Dublin 2, Ireland received on 20/06/2013.
21/07/2015 Request for grant a Supplementary Protection Certificate, citing Patent number 1641822 as the relevant basic patent, in respect of the product Secukinumab filed on 13/07/2015. Reference number of request is 2015/040.
26/10/2016 Request for grant a Supplementary Protection Certificate, citing Patent number 1641822 as the relevant basic patent, in respect of the product Ixekizumab filed on 24/10/2016. Reference number of request is 2016/042.
17/04/2020 Request for grant of Supplementary Protection Certificate No. 2015/040 withdrawn on 17/04/2020.
17/04/2020 Request for grant of Supplementary Protection Certificate No. 2016/042 withdrawn on 17/04/2020.
30/07/2020 Status on register changed from Granted to Revoked by EPO with legal effect from 10/1/2020.
29/09/2020 Year 17 renewal fee has been refunded and removed as the patent was revoked by the EPO with effect from 10/01/2020.Overpayment recovered from EPO with Qtr 3 2020 renewals payment.